Skip to main content
Signal8

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

$IRONPress releaseJun 9, 2026, 8:30 AM ET

Disc Medicine completed a Type A meeting with the FDA regarding the Complete Response Letter for its bitopertin NDA in erythropoietic protoporphyria. The company and the FDA agreed that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response and potentially support traditional approval.

Key figures

Drug Name
bitopertin
Phase Of Trial
Phase 3
Apollo data expected
Q4 2026
Fda decision expected
mid-2027
Crl response submission
end of 2026

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.